Aclarion names Jason Brosniak commercial director for eastern U.S.

Aclarion Inc. (NASDAQ: ACON, ACONW) appointed Jason Brosniak as Commercial Director for the Eastern U.S. to support expansion of its Nociscan platform for chronic low back pain diagnosis.

Brosniak brings over 20 years of commercial experience in medical technology, including roles at Relievant Medsystems, Kyphon, and Intrinsic Therapeutics. His background includes launching technologies across spine, orthopedics, and pain management sectors.

"The growing demand for Nociscan through real-world evidence trials, and the national CLARITY randomized controlled trial, necessitates additional commercial resources in the densely populated Eastern U.S.," said Brent Ness, CEO of Aclarion.

Aclarion's Nociscan is a software platform that uses magnetic resonance spectroscopy data to help physicians identify painful discs in the lumbar spine through chemical biomarkers. The technology processes MRS data from MRI machines through cloud-based algorithms.

The appointment follows the recent naming of Dan Isherwood as UK Commercial Director. The company states it aims to expand access for what it estimates as 266 million people globally who suffer from chronic low back pain.

Aclarion is a healthcare technology company based in Broomfield, Colorado, that develops biomarker-based diagnostic tools using augmented intelligence algorithms.

You May Also Be Interested In

• Lowe's names five executive vice presidents effective Sept. 1
• EagleOne Metals raises private placement ceiling to $225,199
• Coinbase expands board to ten with appointment of Anthony Armstrong